NEW YORK--(BUSINESS WIRE)--Enzo Biochem, Inc., (NYSE: ENZ) today reported that the Board of Patent Appeals and Interferences of the United States Patent and Trademark Office has issued a Decision denying a Request for Rehearing filed by Siemens Healthcare Diagnostics (NYSE:SI) in a patent interference proceeding relating to Enzo Life Science’s application for nucleic acid signal amplification and Siemens U.S. Patent No. 5,124,246, relating to branched DNA (bDNA) diagnostic systems.
